Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
HTBX partnership or buyout expected very soon here......
HHS awards $94 million to health centers to help treat the prescription opioid abuse and heroin epidemic in America
Today, Health and Human Services (HHS) Secretary Sylvia M. Burwell announced $94 million in Affordable Care Act funding to 271 health centers in 45 states, the District of Columbia, and Puerto Rico to improve and expand the delivery of substance abuse services in health centers, with a specific focus on treatment of opioid use disorders in underserved populations.
“The opioid epidemic is one of the most pressing public health issues in the United States today,” said Secretary Burwell. “Expanding access to medication-assisted treatment and integrating these services in health centers bolsters nationwide efforts to curb opioid misuse and abuse, supports approximately 124,000 new patients accessing substance use treatment for recovery and helps save lives.”
The abuse of and addiction to opioids, such as heroin and prescription pain medication, is a serious and increasing public health problem. Approximately 4.5 million people in the United States were non-medical prescription pain reliever users in 2013, and an estimated 289,000 were current heroin users. HHS also estimates the number of unintentional overdose deaths from prescription pain medications has nearly quadrupled from 1999 to 2013, and deaths related to heroin increased 39 percent between 2012 and 2013.
Administered by the HHS Health Resources and Services Administration (HRSA), these awards to health centers across the country will increase the number of patients screened for substance use disorders and connected to treatment, increase the number of patients with access to MAT for opioid use and other substance use disorder treatment, and provide training and educational resources to help health professionals make informed prescribing decisions. This $94 million investment is expected to help awardees hire approximately 800 providers to treat nearly 124,000 new patients.
“Health centers treat some of the most at-risk patients in the country,” said HRSA Acting Administrator Jim Macrae. “These awards position health centers to be at the forefront of the fight against opioid abuse in underserved communities.”
Research demonstrates that a whole-patient approach to treatment through a combination of medication and counseling and behavioral therapies is most successful in treating opioid use disorders. In 2014, over 1.3 million people received behavioral health services at health centers, This represents a 75 percent increase since 2008 and was made possible with support from the Affordable Care Act (ACA) and the Recovery Act. Today’s funding builds upon and leverages these previous investments by providing support to health centers to improve and expand the delivery of MAT substance abuse services in an integrated primary care/behavioral health model with a specific focus on treatment of opioid use disorders in underserved populations.
Today, over 1,300 health centers operate approximately 9,000 service delivery sites in every U.S. state, D.C., Puerto Rico, the Virgin Islands and the Pacific Basin; these health centers employ more than 170,000 staff who provide care for nearly 23 million patients. In 2014, health centers provided behavioral health services to more than 1.3 million patients, including those in need of substance abuse services.
“HRSA's innovative investment in the delivery of medication-assisted treatment for substance use disorders affirms the importance of behavioral health to overall health,” said Kana Enomoto, Acting Administrator of the Substance Abuse and Mental Health Services Administration (SAMHSA).
Addressing the opioid crisis is a top priority for the Administration and the Department. The Department is focused on three key areas: improving opioid prescribing practices, increasing the use of naloxone, and increasing access to MAT. In addition, the President has made addressing the prescription opioid abuse and heroin epidemic a top priority and issued a Presidential Memorandum last year on improving access to medication-assisted treatment (MAT) for opioid use disorders. Today’s awards are an example of HHS taking every available step to expand access to MAT. Building on these efforts, the President’s Budget includes a $1.1 billion initiative to help ensure that all individuals with opioid use disorders who want treatment are able to access it.
To view a list of the award winners, visit: http://bphc.hrsa.gov/programopportunities/fundingopportunities/substanceabuse/fy16awards.html
For more information on the Department’s key areas of focus to address the opioids crisis, visit: http://www.hhs.gov/news/press/2015pres/03/20150326a.html
To learn more about HRSA’s Health Center Program, visit http://bphc.hrsa.gov/about/index.html
To find a health center in your area, visit http://findahealthcenter.hrsa.gov/
###
Thanks you!
When are P 2 results expected?
Where does everyone thinks this goes with good 12 week results?
When are week 12 results being released?
I hope so too! Everything I heard seemed like there's a lot of big potential for 2016. Any other opinions?
I can't see the slides can only listen but they big mention a big pharma partner but couldn't mention the name quite yet.
I ripped some off the top at 10.02 from 6.60 but held 500 just see where this one ends up.
Think we see this up trend continue tomorrow?
Nice! Great job with this one!
The FDA don't give out Orphan Drug Designation to fake companies and I highly doubt Dana Farber would conduct a trial with a fraudulent company......
September full data read out
Good work!!
CTIX continues to run! Do your DD they have a few potential blockbusters in there pipeline!
Anyone holding AVXL through 07/22 data?
FDA website updated CTIX Kevetrin Orphan Drug Designation but no update from company just yet........
Bob is results are good 07/22 where do you see PPS going?
Any upcoming catalyst?
Any catalyst coming up after trial failure?
I did too! I initially bought 25,000 at .35 and sold 10,000 at 1.05. I wish I held but was able to get my full investment back and 15,000 FREE shares.
Do you pass the 3.00 mark tomorrow?
$heff when is data expected to be released?
Great stock! I was lucky enough to get in mid 3s when Anabel Simimy from Stifel rated it a buy with a 12 target price. I sold wayyyyyyyy to early but great to see the progress they have made. She does great DD!
CLDC any thoughts? Piper 21 TP/Stifel 15 TP and William Blair 22......
Where do you see the pps after the MIDS report is released?
I missed the early run from .21 but think this will pay off in time
Same here avg price .32 a little higher then I wanted but I'll take it!
PTBI out at 10.50 and holding a free 1000 shares after making 100% of my initial investment! Jbem777 hell of a job!
Great pick once AGAIN Bob! 3.00 avg cost and out of 1/2 my position at 5.44 lets see where this one goes. Any thoughts?
Picked up some PTBI at 2.80 at close hope to see this run back up
Does anyone think by Actavis announcing topline Phase 3 trail results for single dose Dalvance could be the reason for such SP falling so much Friday? Just a thought any opinions?
Bob when data expected?
Bob still holding BIAD?
I'm holding 30k wish I had more! Hope this is enough to join the retire early club!
Thanks Bob! Great work as usual!
New unfortunately Bob! I had an order in last two days that never was filled! Hoping to add 50k
Hoping to get in at open at .24
Bob you see this hitting the .30s soon?